Effect of l-carnitine on the size of low-density lipoprotein particles in type 2 diabetes mellitus patients treated with simvastatin

Metabolism: Clinical and Experimental

Volumn 58, Issue 11, 2009, Pages 1618-1623

  Malaguarnera, Mariano ^a   Vacante, Marco ^a   Motta, Massimo ^a   Malaguarnera, Michele ^a   Li Volti, Giovanni ^a   Galvano, Fabio ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; CARNITINE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PARTICLE SIZE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; AGED; BLOOD; METABOLISM; MIDDLE AGED;

ADULT; AGED; BLOOD GLUCOSE; CARNITINE; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PARTICLE SIZE; SIMVASTATIN;

EID: 70449707694     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2009.05.014     Document Type: Article

References (37)

1. Wild S., Roglic G., Green A., Sicree R., and King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 (2004) 1047-1053
2. Nielsen L.B. Transfer of low density lipoprotein into the arterial wall and risk of atherosclerosis. Atherosclerosis 123 (1996) 1-15
3. Galeano N.F., Al-Haideri M., Keyserman F., Rumsey S.C., and Deckelbaum R.J. Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: a potential mechanism for increased atherogenicity. J Lipid Res 39 (1998) 1263-1273
4. St-Pierre A.C., Cantin B., Dagenais G.R., Mauriège P., Bernard P.M., Després J.P., and Lamarche B. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Québec Cardiovascular Study. Arterioscler Thromb Vasc Biol 25 (2005) 553-559
5. Landray M.J., Sagar G., Muskin J., Murray S., Holder R.L., and Lip G.Y. Association of atherogenic low-density lipoprotein subfractions with carotid atherosclerosis. QJM 91 (1998) 345-351
6. Lamarche B., St-Pierre A.C., Ruel I.L., Cantin B., Dagenais G.R., and Després J.P. A prospective, population-based study of low density lipoprotein particle size as a risk factor for ischemic heart disease in men. Can J Cardiol 17 (2001) 859-865
7. Goldstein J.L., and Brown M.S. Regulation of the mevalonate pathway. Nature 343 (1990) 425-430
8. Bilheimer D.W., Grundy S.M., Brown M.S., and Goldstein J.L. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci U S A 80 (1983) 4124-4128
9. Topol E.J. Intensive statin therapy-a sea change in cardiovascular prevention. N Engl J Med 350 (2004) 1562-1564 [Proc. Natl. Acad. Sci. USA 1983; 80: 4124-4128]
10. Schaefer E.J., McNamara J.R., Tayler T.J., Daly A., Gleason J.L., Seman L.J., et al. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects. Am J Cardiol 93 (2004) 31-39
11. Jones P.H., Davidson M.H., Stein E.A., Bays H.E., McKenney J.M., Miller E., et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 92 (2003) 152-160
12. Pyorala K., Pedersen T.R., Kjekshus J., Faergeman O., Olsson A.G., and Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20 (1997) 614-620
13. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil H.A., Livingstone S.J., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
14. Collins R., Armitage J., Parish S., Sleigh P., and Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo controlled trial. Lancet 361 (2003) 2005-2016
15. Wakatsuki A., Okatani Y., and Ikenoue N. Effects of combination therapy with estrogen plus simvastatin on lipoprotein metabolism in postmenopausal women with type IIa hypercholesterolemia. Atherosclerosis 150 (2000) 103-111
16. Tsimihodimos V., Karabina S.A., Tambaki A., Bairaktari E., Achimastos A., Tselepis A., et al. Effect of atorvastatin on the concentration, relative distribution, and chemical composition of lipoprotein subfractions in patients with dyslipidemias of type IIA and IIB. J Cardiovasc Pharmacol 42 (2003) 304-310
17. Baldassarre S., Scruel O., Deckelbaum R.J., Dupont I.E., Ducobu J., and Carpentier Y.A. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin. Int J Cardiol 104 (2005) 338-345
18. Rebouche C.J. Is carnitine an essential nutrient for humans?. J Nutr 116 (1986) 704-706
19. De Gaetano A., Mingrone G., Castagneto M., and Calvani M. Carnitine increases glucose disposal in humans. J Am Coll Nutr 18 (1999) 289-295
20. Borum P.R. Carnitine. Annu Rev Nutr 3 (1983) 233-259
21. Frits I.B. Carnitine and its role in fatty acid metabolism. Adv Lipid Res 64 (1963) 285-334
22. Bremer J. Carnitine-metabolism and functions. Physiol Rev 63 (1983) 1420-1480
23. McGarry J.D., and Foster D.W. Systemic carnitine deficiency. N Engl J Med 303 (1980) 1413-1415
24. Nosadini R., Angelini C., Trevisan C., Vigili de Kreutzenberg S., Fioretto P., Trevisan R., et al. Glucose and ketone body turnover in carnitine-palmitoyl-transferase deficiency. Metabolism 36 (1987) 821-826
25. Engel A.G., and Rebouche C.J. Carnitine metabolism and inborn errors. J Inherit Metab Dis 7 (1984) 38-43
26. Bohmer T., Bergrem H., and Eiklid K. Carnitine deficiency induced during intermittent haemodialysis for renal failure. Lancet 21 (1978) 126-128
27. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 28 (2005) S37-S42
28. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
29. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 277 (1997) 925-926
30. Gaw A., Packard C.J., Murray E.F., Lindsay G.M., Griffin B.A., Caslake M.J., et al. Effects of simvastatin on apoB metabolism and LDL subfraction distribution. Arterioscler Thromb Vasc Biol 13 (1993) 170-189
31. Nigon F., Lesnik P., Rouis M., and Chapman M.J. Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor. J Lipid Res 32 (1991) 1741-1753
32. Reaven G.M., Chen Y.D., Jeppesen J., Maheux P., and Krauss R.M. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest 92 (1993) 141-146
33. Howard B.V., and Howard W.J. LDL cholesterol and troglitazone therapy. Diabetes Care 21 (1998) 2201-2203
34. Mykkänen L., Kuusisto J., Haffner S.M., Laakso M., and Austin M.A. LDL size and risk of coronary heart disease in elderly men and women. Arterioscler Thromb Vasc Biol 19 (1999) 2742-2748
35. Lopaschuk G. Regulation of carbohydrate metabolism in ischemia and reperfusion. Am Heart J 139 (2000) S115-S119
36. Dellow W.J., Chambers S.T., Lever M., Lunt H., and Robson R.A. Elevated glycine betaine excretion in diabetes mellitus patients is associated with proximal tubular dysfunction and hyperglycemia. Diabetes Res Clin Pract 43 (1999) 91-99
37. Malaguarnera M., Vacante M., Avitabile T., Malaguarnera M., Cammalleri L., and Motta M. l-carnitine supplementation reduces the oxidated LDL cholesterol in diabetic patients. Am J Clin Nutr 89 (2009) 71-76